Abstract
Embryonal tumors (ETs) of the central nervous system (CNS) comprise a large heterogeneous group of highly malignant tumors that predominantly affect children and adolescents. Currently, the neoplasms classified as ET are the medulloblastoma (MB), embryonal tumors with multilayered rosettes (ETMR), medulloepithelioma (ME), CNS neuroblastoma (NB), CNS ganglioneuroblastoma (GNB), atypical teratoid/rhabdoid tumors (AT/RT), and CNS embryonal tumors with rhabdoid features. All these tumors are classified as malignant-grade IV neoplasms, and the prognosis of patients with these neoplasms is very poor. Currently, except for the histological classification of MB, the recently utilized WHO classification accepts a novel molecular classification of MBs into four distinct molecular subgroups: wingless/integrated (WNT)-activated, sonic hedgehog (Shh), and the numerical Group3 and Group 4. The combination of both histological and genetic classifications has substantial prognostic significance, and patients are categorized as low risk with over 90% survival, the standard risk with 75–90% survival, high risk with 50–75% survival, and very high risk with survival rate lower than 50%. Children under three years are predominantly affected by AT/RT and represent about 20% of all CNS tumors in this age group. AT/RT is typically located in the posterior fossa (mainly in cerebellopontine angle) in 50–60% of the cases. The pathogenesis of this neoplasm is strongly associated with loss of function of the SMARCB1 (INI1, hSNF5) gene located at the 22q11.23 chromosome, or very rarely with alterations in (SMARCA4) BRG1 gene. The cells of this neoplasm resemble those of other neuronal tumors, and hence, immunochemistry markers have been utilized, such as smooth muscle actin, epithelial membrane antigen, vimentin, and lately antibodies for INI1. ETMRs are characterized by the presence of ependymoblastic rosettes formed by undifferentiated neuroepithelial cells and neuropil. The tumorigenesis of ETMRs is strongly related to the amplification of the pluripotency factor Chr19q13.41 miRNA cluster (C19MC) present in around 90% of the cases. Additionally, the expression of LIN28A is a highly sensitive and specific marker of ETMR diagnosis, as it is overexpressed in almost all cases of ETMR and is related to poor patient outcomes. The treatment of patients with ETs includes a combination of surgical resection, radiotherapy (focal or craniospinal), and chemotherapeutic agents. Currently, there is a trend to reduce the dose of craniospinal irradiation in the treatment of low-risk MBs. Novel targeted therapies are expected in the treatment of patients with MBs due to the identification of the main driver genes. Survival rates vary between ET types and their subtypes, with ganglioneuroblastoma having over 95% 5-year survival rate, while ATRT is probably linked with the worst prognosis with a 30% 5-year survival rate.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Alexiou GA, Moschovi M, Stefanaki K, Sfakianos G, Prodromou N (2011) Epidemiology of pediatric brain tumors in Greece (1991–2008). Experience from the Agia Sofia Children’s Hospital. Cent Eur Neurosurg 72:1–4. https://doi.org/10.1055/s-0030-1268495
Arslanoglu A, Aygun N, Tekhtani D, Aronson L, Cohen K, Burger PC, Yousem DM (2004) Imaging findings of CNS atypical teratoid/rhabdoid tumors. Am J Neuroradiol 25:476–480
Bansil R, Kindra A, Mansoori N, Sinha S, Bhaskar S, Agarwal P (2016) Cerebral medulloepithelioma: a rare aggressive brain tumor in child—a case report. Indian J Neurosurg 5:055–058
Baroni LV et al (2020) Bridging the treatment gap in infant medulloblastoma: molecularly informed outcomes of a globally feasible regimen. Neuro Oncol 22:1873–1881
Begemann M et al (2020) Germline GPR161 mutations predispose to pediatric medulloblastoma. J Clin Oncol (Official Journal of the American Society of Clinical Oncology) 38:43–50 https://doi.org/10.1200/jco.19.00577
Berger MS, Edwards MS, Wara WM, Levin VA, Wilson CB (1983) Primary cerebral neuroblastoma: long-term follow-up review and therapeutic guidelines. J Neurosurg 59:418–423
Bianchi F, Tamburrini G, Gessi M, Frassanito P, Massimi L, Caldarelli M (2018) Central nervous system (CNS) neuroblastoma. A case-based update. Child’s Nerv Syst 34:817–823
Borowska A, Jóźwiak J (2016) Medulloblastoma: molecular pathways and histopathological classification. Arch Med Sci (AMS) 12:659
Bouali S, Zehani A, Mahmoud M, Said IB, Kallel J, Jemel H (2018) Embryonal tumor with multilayered rosettes: illustrative case and review of the literature. Childs Nerv Syst 34:2361–2369
Ceccom J et al (2014) Embryonal Tumor with multilayered rosettes: diagnostic tools update and review of the literature. Clin Neuropathol 33:15–22. https://doi.org/10.5414/np300636
Dangouloff-Ros V et al (2019) CT and multimodal MR imaging features of embryonal tumors with multilayered rosettes in children. Am J Neuroradiol (AJNR) 40:732–736. https://doi.org/10.3174/ajnr.A6001
Eberhart CG, Burger PC (2003) Anaplasia and grading in medulloblastomas. Brain Pathol (Zurich, Switzerland) 13:376–385. https://doi.org/10.1111/j.1750-3639.2003.tb00037.x
Farwell JR, Dohrmann GJ, Flannery JT (1984) Medulloblastoma in childhood: an epidemiological study. J Neurosurg 61:657–664. https://doi.org/10.3171/jns.1984.61.4.0657
Fruhwald M, Plass C (2002) Metastatic medulloblastoma—therapeutic success through molecular target identification? Pharmacogenomics J 2:7–10
Ginn KF, Gajjar A (2012) Atypical teratoid rhabdoid tumor: current therapy and future directions. Front Oncol 2:114
Hesham D, El-Naggar S (2020) Transcriptomic analysis revealed an emerging role of alternative splicing in embryonal tumor with multilayered rosettes. Genes 11. https://doi.org/10.3390/genes11091108
Hoffman M, Park T (1983) Medulloblastoma: clinical presentation and management. J Neurosurg 8:543–552
Holdhof D et al (2021) Atypical teratoid/rhabdoid tumors (ATRTs) with SMARCA4 mutation are molecularly distinct from SMARCB1-deficient cases. Acta Neuropathologica 141:291–301. https://doi.org/10.1007/s00401-020-02250-7
Ito J et al (2020) Central nervous system ganglioneuroblastoma harboring MYO5A-NTRK3 fusion. Brain Tumor Pathol 37:105–110. https://doi.org/10.1007/s10014-020-00371-1
Johann PD et al (2016) Atypical teratoid/rhabdoid tumors are comprised of three epigenetic subgroups with distinct enhancer landscapes. Cancer Cell 29:379–393. https://doi.org/10.1016/j.ccell.2016.02.001
Juraschka K, Taylor MD (2019) Medulloblastoma in the age of molecular subgroups: a review. J Neurosurg Pediatr 24:353–363. https://doi.org/10.3171/2019.5.peds18381
Koeller KK, Rushing EJ (2003) From the archives of the AFIP: medulloblastoma: a comprehensive review with radiologic-pathologic correlation. Radiographics 23:1613–1637
Kool M et al (2014) Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition. Cancer Cell 25:393–405. https://doi.org/10.1016/j.ccr.2014.02.004
Korshunov A et al (2021) Molecular analysis of pediatric CNS-PNET revealed nosologic heterogeneity and potent diagnostic markers for CNS neuroblastoma with FOXR2-activation. Acta Neuropathologica Commun 9:20. https://doi.org/10.1186/s40478-021-01118-5
Korshunov A et al (2012) LIN28A immunoreactivity is a potent diagnostic marker of embryonal tumor with multilayered rosettes (ETMR). Acta Neuropathologica 124:875–881. https://doi.org/10.1007/s00401-012-1068-3
Kram DE, Henderson JJ, Baig M, Chakraborty D, Gardner MA, Biswas S, Khatua S (2018) Embryonal tumors of the central nervous system in Children: the era of targeted therapeutics. Bioengineering (Basel, Switzerland) 5. https://doi.org/10.3390/bioengineering5040078
Kumar A, Abbas AK, Jon C (2015) Aster: Robbins and Cotran pathologic basis of disease. Professional Edition
Lambo S, von Hoff K, Korshunov A, Pfister SM, Kool M (2020) ETMR: a tumor entity in its infancy. Acta Neuropathologica, 1–18
Louis DN et al (2016) The World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131:803–820. https://doi.org/10.1007/s00401-016-1545-1
Massimino M et al (2016) Childhood medulloblastoma. Crit Rev Oncol/Hematol 105:35–51
Mirza FA, Synder B, Smith VD, Vasquez RA (2018) Pediatric supratentorial ganglioneuroblastoma: case report and review of literature. World Neurosurg 113:261–266
Moeller KK, Coventry S, Jernigan S, Moriarty T (2007) Atypical teratoid/rhabdoid tumor of the spine. Am J Neuroradiol 28:593–595
Molloy PT et al (1996) Central nervous system medulloepithelioma: a series of eight cases including two arising in the pons. J Neurosurg 84:430–436
Müller K et al (2011) Curative treatment for central nervous system medulloepithelioma despite residual disease after resection. Strahlenther Onkol 187:757–762
Northcott PA et al (2017) The whole-genome landscape of medulloblastoma subtypes. Nature 547:311–317. https://doi.org/10.1038/nature22973
Oka H, Scheithauer BW (1999) Clinicopathological characteristics of atypical teratoid/rhabdoid tumor. Neurologia Medico-chirurgica 39:510–518
Pedram M, Vafaie M, Fekri K, Haghi S, Rashidi I, Pirooti C (2013) Cerebellar neuroblastoma in 2.5 years old child. Iran J Cancer Prevention 6:174–176
Pei Y-C et al (2019a) Embryonal tumor with multilayered rosettes, C19MC-altered (ETMR): a newly defined pediatric brain tumor. Int J Clin Exp Pathol 12:3156
Pei YC et al (2019b) Embryonal tumor with multilayered rosettes, C19MC-altered (ETMR): a newly defined pediatric brain tumor. Int J Clin Exp Pathol 12:3156–3163
Reddy AT (2005) Atypical teratoid/rhabdoid tumors of the central nervous system. J Neurooncol 75:309–313
Reddy AT et al (2020) Efficacy of high-dose chemotherapy and three-dimensional conformal radiation for atypical teratoid/rhabdoid tumor: a report from the children’s oncology group trial ACNS0333. J Clin Oncol (Official Journal of the American Society of Clinical Oncology) 38:1175–1185. https://doi.org/10.1200/jco.19.01776
Richards A et al (2020) Outcomes with respect to extent of surgical resection for pediatric atypical teratoid rhabdoid tumors. Child’s Nerv Syst (ChNS: Official Journal of the International Society for Pediatric Neurosurgery) 36:713–719. https://doi.org/10.1007/s00381-019-04478-5
Robinson GW et al (2018) Risk-adapted therapy for young children with medulloblastoma (SJYC07): therapeutic and molecular outcomes from a multicentre, phase 2 trial. Lancet Oncol 19:768–784
Rorke LB, Packer RJ, Biegel JA (1996) Central nervous system atypical teratoid/rhabdoid tumors of infancy and childhood: definition of an entity. J Neurosurg 85:56–65
Steenberge SP, Prayson RA (2014) Pediatric cerebral ganglioneuroblastoma. J Clin Neurosci 21:2023–2025
Stefanaki K, Alexiou GA, Stefanaki C, Prodromou N (2012) Tumors of central and peripheral nervous system associated with inherited genetic syndromes. Pediatr Neurosurg 48:271–285. https://doi.org/10.1159/000351546
Strother D (2005) Atypical teratoid rhabdoid tumors of childhood: diagnosis, treatment and challenges. Expert Rev Anticancer Therapy 5:907–915
Tekautz TM et al (2005) Atypical teratoid/rhabdoid tumors (ATRT): improved survival in children 3 years of age and older with radiation therapy and high-dose alkylator-based chemotherapy. J Clin Oncol (Official Journal of the American Society of Clinical Oncology) 23:1491–1499. https://doi.org/10.1200/jco.2005.05.187
Thompson EM, Ashley D, Landi D (2020) Current medulloblastoma subgroup specific clinical trials. Transl Pediatr 9:157–162. https://doi.org/10.21037/tp.2020.03.03
Torchia J et al (2015) Molecular subgroups of atypical teratoid rhabdoid tumours in children: an integrated genomic and clinicopathological analysis. Lancet Oncol 16:569–582. https://doi.org/10.1016/s1470-2045(15)70114-2
Tulla M, Berthold F, Graf N, Rutkowski S, von Schweinitz D, Spix C, Kaatsch P (2015) Incidence, trends, and survival of children with embryonal tumors. Pediatrics 136:e623-632. https://doi.org/10.1542/peds.2015-0224
Yariş N, Yavuz MN, Reis A, Yavuz AA, Okten A (2004) Primary cerebral neuroblastoma: a case treated with adjuvant chemotherapy and radiotherapy. Turk J Pediatr 46:182–185
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Lampros, M., Alexiou, G.A. (2023). Brain and Spinal Cord Tumors of Embryonic Origin. In: Rezaei, N., Hanaei, S. (eds) Human Brain and Spinal Cord Tumors: From Bench to Bedside. Volume 2. Advances in Experimental Medicine and Biology, vol 1405. Springer, Cham. https://doi.org/10.1007/978-3-031-23705-8_15
Download citation
DOI: https://doi.org/10.1007/978-3-031-23705-8_15
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-23704-1
Online ISBN: 978-3-031-23705-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)